VH-3810109 is under clinical development by ViiV Healthcare and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VH-3810109’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GSK-3810109 is under development for the treatment of human immunodeficiency virus (HIV) infections. The drug candidate is a broadly neutralizing antibody acts by targeting gp120. It is administered through intravenous or subcutaneous route.
ViiV Healthcare overview
ViiV Healthcare (ViiV), formerly Glaxosmithkline Newco, is a research company. It researches and developes the use of HIV medicines. The company offers nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitor, protease inhibitors, and CCR5 antagonist for the treatment of AIDS. Its products include dolutegravir, zidovudine, fosamprenavi, maraviroc, abacavir, and nelfinavir. ViiV also offers various fellowship programs for primary care HIV specialists. The company partners with HIV community to provide education and support services to people with AIDS. It operates in Japan, the US, the Netherlands, the UK, Australia, Portugal, China, Switzerland, Puerto Rica and Belgium. ViiV is headquartered in Brentford, the UK.
For a complete picture of VH-3810109’s drug-specific PTSR and LoA scores, buy the report here.